# GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC

Source: https://onco.cc/trials/nct07802184/  
OnCo record `nct07802184` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of retlirafusp alfa, rivoceranib (apatinib), gemcitabine and nab-paclitaxel in pancreatic cancer, run by West China Hospital, not yet recruiting.

## Summary

GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC is a phase 1/2, interventional study registered as NCT07802184 by West China Hospital, with a registry enrolment figure of 45 participants, started 2026-09-10 and due to reach its primary completion in 2029-01-01. Interventions recorded: SHR-1701; Apatinib; gemcitabine; Nab-paclitaxel. Conditions listed: Locally Advanced Pancreatic Cancer; Metastatic Pancreatic Cancer. Primary outcome: Recommended Phase II Dose (RP2D); Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: "1\) Age 18-75 years, regardless of sex; 2) patients with histologically confirmed pancreatic ductal adenocarcinoma (PDAC); 3) previously untreated patients with unresectable locally advanced or metastatic PDAC, with at least one measurable lesion according to RECIST v1". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07802184
- Phase: 1/2
- Setting: GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center, Open-Label, Phase Ib/II Trial
- Sponsor: West China Hospital
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT07802184: https://clinicaltrials.gov/study/NCT07802184

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Retlirafusp alfa](https://onco.cc/drugs/retlirafusp-alfa/), [Rivoceranib (apatinib)](https://onco.cc/drugs/rivoceranib/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07802184.json